Loading company
Mereo BioPharma Group plc
MREO · Nasdaq · ·
Next earnings: November 9, 2026
$0.37+1.5%Sep 29 close
- 1M
- +47.5%
- 6M
- +17.8%
- 1Y
- -81.9%
- 5Y
- -85.0%
MREO · Nasdaq · ·
Next earnings: November 9, 2026
$0.37+1.5%Sep 29 close
Mereo BioPharma Group plc is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$7M | -$14.6M | +52.07% |
| Profit per share | -$0.05 | -$0.10 | +50.00% |
| Free Cash Flow | -$6M | -$7.7M | +21.02% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The partnership with Sentynl Therapeutics which we announced earlier today marks a significant milestone for our alvelestat program and for the Company as a whole. We are now working together to refine the design of the global Phase 3 study for our potential first-in-class oral therapy for AATD-LD and look forward to a continued close collaboration during the short option period. Assuming exercise of the license option by Sentynl, we plan to initiate the Phase 3 trial in early 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Mereo BioPharma Group plc’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Mereo BioPharma Group plc has no earnings call transcript available.